The company announced updated data from the OPTIC extension study of patients diagnosed with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco.
Adverum Biotechnologies Inc presented updated data from the OPTIC extension study of patients with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting in San Francisco, California.
According to the company, a summary of previously announced aflibercept protein levels from the LUNA study was also presented.
Laurent Fischer, MD, president and CEO of Adverum Biotechnologies, announced the company was pleased with the development of a treatment option that has the potential to be safe, efficacious and much less burdensome for patient.
“These efforts are now supported by the most mature dataset in wet AMD IVT gene therapy, with the OPTIC safety and efficacy data now sustained out to 3 years,” Fischer said in the company’s news release. “Ixo-vec demonstrated a robust improvement in outcome measures while maintaining a favorable safety profile, particularly at the 2E11 dose, which we have advanced to our Phase 2 LUNA trial. We are particularly encouraged by the continuous and consistent aflibercept protein levels observed at up to 4.5 years post-treatment. These data highlight the potential for patients to experience life-long clinical benefit after a single IVT treatment with minimal or no need for additional injections and showcase the potentially transformative impact of gene therapy.”
OPTIC 3-year data highlights
LUNA aflibercept protein data highlights, baseline characteristics and program milestones
Carl Regillo, MD, FACS, chief of the Retina Service at Wills Eye Hospital and presenter of the data at the AAO Annual Meeting, noted the long-term follow-up data from the OPTIC trial continue to affirm that Ixo-vec offers a potentially transformational treatment for wet AMD.
“A favorable benefit-risk profile resulting in an 84% reduction in annualized anti-VEGF injections was demonstrated in participants receiving the 2E11 dose, with 53% of patients continuing to be free from supplemental injections at 3 years after a single IVT injection,” he said in the news release. “Taken together, the efficacy and safety at the 2E11 dose in the OPTIC trial underscore Ixo-vec's potential as a promising treatment option for wet AMD patients addressing real-world unmet needs. I look forward to learning more from the ongoing Phase 2 LUNA trial.”